Related Experiment Video

Updated: Jun 28, 2025

Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice
11:10

Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice

Published on: November 16, 2011

94.4K

Metabolic control in type 2 diabetic patients treated with empagliflozin: A case series

Wilfredo Navarrete1, Pilar Durruty2, Eileen Andrade1

  • 1Consultorio Adosado de Especialidades, Hospital Peñaflor, Peñaflor, Chile.

Medwave
|April 17, 2024
PubMed
Abstract

Insights

Empagliflozin effectively improved glycemic control in type 2 diabetes mellitus patients requiring insulin. This sodium-glucose cotransporter type 2 inhibitor showed significant HbA1c reduction with a manageable safety profile.

Area of Science:

  • Endocrinology
  • Metabolic Diseases
  • Pharmacology

Background:

  • Type 2 diabetes mellitus (T2DM) is a widespread condition linked to significant morbidity and mortality.
  • Inadequate glycemic control remains a challenge in T2DM management.
  • Sodium-glucose cotransporter type 2 inhibitors (SGLT2is) represent a novel therapeutic strategy for T2DM.

Purpose of the Study:

  • To evaluate the efficacy of empagliflozin in T2DM patients with insulin requirements at Peñaflor Hospital.
  • Primary objective: assess the impact of empagliflozin on glycosylated hemoglobin A1c (HbA1c).
  • Secondary objectives: analyze HbA1c achievement below 7.5%, changes in glomerular filtration rate, and urinary albumin excretion.

Main Methods:

  • Retrospective review of clinical records for patients treated with empagliflozin from November 2019 to June 2023.
  • Average patient follow-up duration of 19 months (range: 16.3-40 months).
  • Statistical analysis included paired t-tests or Wilcoxon tests to compare HbA1c values across follow-up periods.

Main Results:

  • The study included 58 patients (15 men, 43 women) with an average age of 58.5 years.
  • Baseline HbA1c of 10.3% decreased to 8.98% at 18-24 months follow-up, a significant reduction of 1.27% (p=0.002).
  • Urinary tract infection was the most frequently reported adverse effect.

Conclusions:

  • Empagliflozin demonstrated effectiveness in improving glycemic control for T2DM patients on insulin therapy.
  • The treatment was associated with a notable reduction in HbA1c levels.
  • Empagliflozin exhibited a favorable safety profile with minimal adverse events.

More Related Videos

A Zebrafish Model of Diabetes Mellitus and Metabolic Memory10:03

A Zebrafish Model of Diabetes Mellitus and Metabolic Memory

Published on: February 28, 2013

25.8K
Improving IV Insulin Administration in a Community Hospital12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

18.8K

Related Concept Videos

Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
275
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.3K
Carbohydrate Metabolism01:36

Carbohydrate Metabolism

Carbohydrates are polymers composed of molecules containing atoms of carbon, hydrogen and oxygen. One gram of carbohydrate can provide four kilo-calories of energy, which makes it the most efficient instant energy source.
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in...
11.1K
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
195
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
319
Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
2.6K